Visit us at BIO 2022!

Serina Therapeutics CEO, Randall Moreadith, MD, PhD, joins an industry panel to discuss the exciting future of lipid nanoparticle (LNP) drug delivery technology.

Learn More

Serina Therapeutics

Relentless curiosity drives life-changing breakthroughs

Science
Investors

POZ Platform™

Our proprietary POZ platform technology has been designed for programmable, targeted delivery of a broad range of small molecules. The technology has been clinically demonstrated to safely enable continuous drug delivery via a once weekly subcutaneous injection. The POZ platform is broad, customizable and versatile, and can be dosed via IV, SC or IM routes.

Our Science

Central Nervous System (CNS)

We have a pipeline of wholly-owned CNS drug candidates, addressing large markets with significant unmet need.

Lipid Nanoparticles (LNPs)

Our collaborations with partners to advance LNP based drug delivery in mRNA immunology highlights the broad potential of our POZ platform technology.

Antibody-Drugs (ADCs)

POZ enables improved efficacy against Low-Density Targets by Increasing the Drug Antibody Ratio (DAR) of cancer killing cytotoxins.

63

Patents Held

5

Partners

4

IND Candidates

15

Years in Development

We’re pioneering bold new science.

Join us.

Partners
Investors
Scientists